FDA-Authorized Myopia Control Lenses for Children
As of September 25, 2025, the U.S. Food and Drug Administration authorized marketing of the Essilor Stellest eyeglass lenses to correct myopia, commonly referred to as nearsightedness, with or without astigmatism, and to slow the progression of the disease in children 6 to 12 years old at the initiation of treatment.
Why Myopia Matters
Myopia is a chronic disease that affects approximately 40% of the U.S. population, with prevalence increasing rapidly among children and adolescents. When left untreated, this disease can progress to high myopia, which significantly increases the risks of sight-threatening complications, including retinal detachment, myopic maculopathy, glaucoma, and cataracts later in life.
request an appointmentWhat the Clinical Study Showed
The FDA evaluated two years of data from a clinical study that demonstrated the Essilor Stellest eyeglass lenses slowed myopia progression as compared to single vision control lenses. The study measured the change in glasses prescription (spherical equivalent refraction) and the change in the length of the eye (axial length).
- For spherical equivalent refraction, the study showed a 71% reduction in myopia progression at 24 months.
- For axial length, the study showed a 53% reduction in eye elongation at 24 months.
Recommended Wear Time
For optimal effectiveness, children should wear the glasses consistently for at least 10 hours a day, with a minimum of 2 of those hours being collective outdoor time.
Schedule a Myopia Consultation
Ask our team whether myopia management is right for your child. Call us at (702) 685-4320 or request an appointment online.
request an appointment